Filing Details
- Accession Number:
- 0000904454-20-000277
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-06 10:07:47
- Reporting Period:
- 2020-03-04
- Accepted Time:
- 2020-03-06 10:07:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1590560 | Uniqure N.v. | QURE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1711885 | Christian Klemt | C/O Uniqure N.v. Paasheuvelweg 25A Amsterdam P7 11058BP | Chief Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2020-03-04 | 15,750 | $26.41 | 72,768 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2020-03-04 | 13,500 | $52.00 | 59,268 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-03-04 | 2,250 | $54.00 | 57,018 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2020-03-04 | 15,750 | $0.00 | 15,750 | $26.41 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,250 | 2025-09-01 | No | 4 | M | Direct |
Footnotes
- The Stock Option vested 25% on September 1, 2016 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
- The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
Billionaire Hedge Funds
